Refined glycoprotein extracted from human urine, belonging to protease inhibitor. It can inhibit trypsin and other trypsin activities, and is often used in the treatment of pancreatitis. In addition, the product has the functions of stabilizing lysosomal membrane, inhibiting the release of lysosomal enzyme and inhibiting the production of myocardial inhibitory factors, so it can be used in the rescue treatment of acute circulatory failure.
ulinastatin Clinical application and indications
1. Acute pancreatitis;
2. Acute exacerbation of chronic recurrent pancreatitis;
3. Rescue adjuvant medication for acute circulatory failure;
4. Inflammatory factors are important indicators to reflect the severity of severe pneumonia and the immune response of the body. After the combined application of ulinastatin, Zheng Xueying et al. found that TNF-, IL-6 and IL-8 levels in children were significantly reduced.
Elastase derived from polymorphonuclear leukocytes (PMN), tumor necrosis factor (TNF-), and other pro-inflammatory cytokines such as IL-1, IL-6, and IL-8 are closely related: Ulinastatin inhibits the activation of PMN cells, macrophages, and platelets, reducing the degree of inflammatory cell infiltration and the risk of local inflammation spreading throughout the body. In addition, IL-10 is a negative immunoregulatory factor that can directly or indirectly act on CD4+ /CD8+ lymphocytes, thereby inhibiting their proliferation. When the inflammatory response is strong, il-10 expression is inhibited, and the level of IL-10 increases gradually after the inflammation fades away.
In summary, ulinastatin treatment in children with severe pneumonia has a relatively high clinical efficacy and can effectively regulate the serum LEVELS of TNF-, IL-6, IL-8 and IL-10 in children, which is worthy of promotion.